(Q43663330)

25 November 2017

Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia (English)

1 reference

25 November 2017

0 references

0 references

K Kucia

3

0 references

Zbigniew Herman

series ordinal

5

object named as

Z S Herman

1 reference

25 November 2017

J Kowalski

1

1 reference

25 November 2017

P Blada

series ordinal

2

1 reference

25 November 2017

A Madej

series ordinal

4

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

25 November 2017

Schizophrenia Research

1 reference

25 November 2017

50

1 reference

25 November 2017

169-175

1 reference

25 November 2017

3

1 reference

Interleukin-2 modulates evoked release of [3H]dopamine in rat cultured mesencephalic cells

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Partial improvement in negative schizophrenic symptoms after amphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Interleukin-1 alpha in blood has direct access to cortical brain cells

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Differential effect of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Negative selection of human monocytes using magnetic particles covered by anti-lymphocyte antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Murine tumor necrosis factor alpha is transported from blood to brain in the mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Action site of circulating interleukin-1 on the rabbit brain

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

In-vitro immunomodulatory effects of haloperidol and perazine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Short and long-term immunosuppressive effects of clozapine and haloperidol.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Elevated central levels of interleukin-2 in drug-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Pathways and mechanisms for cytokine signaling of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Plasma-soluble interleukin-2 and transferrin receptor in schizoprenia and major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Cellular immunity in schizophrenic patients before and during neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Effect of chronic treatment with recombinant interleukin-2 on the central nervous system of adult and old mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Elevated levels of soluble interleukin 2 receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

No evidence for autoimmunity in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Is schizophrenia caused by excessive production of interleukin-2 and interleukin-2 receptors by gastrointestinal lymphocytes?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

A comprehensive macrophage-T-lymphocyte theory of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Tumor Necrosis Factor Modulates the Inactivation of Catecholamine Secretion in Cultured Sympathetic Neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900156-0

7 January 2021

10.1016/S0920-9964(00)00156-0

Identifiers

DOI

1 reference

25 November 2017

1 reference